CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

Rob Coleman(University of Sheffield), Sarah Brown(University of Leeds), Sacha J. Howell(The Christie NHS Foundation Trust), Emma Rathbone(Calderdale and Huddersfield NHS Foundation Trust), Iain R. Macpherson(Beatson West of Scotland Cancer Centre), Jessica Kendall(University of Leeds), Chris Twelves(University of Leeds), Janet E. Brown(University of Sheffield), Carlo Palmieri(University of Liverpool), A.W. Reid(University of Leeds), Anjana Anand(Nottingham University Hospitals NHS Trust), Louise Flanagan(University of Leeds)
Trials
January 15, 2020
10.1186/s13063-019-3643-6
Cited by 15

Related Papers

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
|The Lancet|2015|477